Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Status:
Completed
Trial end date:
2018-06-14
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a study to assess the safety, tolerability, pharmacokinetics, and
pharmacodynamics of an orally-administered medication to relieve symptoms of constipation
associated with Parkinson's Disease. Ten patients will be enrolled in Phase 1, and will be
studied over an 8-12 week period. Forty patients will be enrolled in Phase 2, and will be
studied over an 8-10 week period. All subjects will receive the study drug during one of the
observational periods of the study.